AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $246.52, giving the company a market capitalization of 435.55B. It carries a P/E multiple of 119.92 and pays a dividend yield of 2.77%.
As of 2026-06-26, AbbVie(ABBV) stock has fluctuated between $243.67 and $249.59. The current price stands at $246.52, placing the stock +1.2% above today's low and -1.2% off the high.
The AbbVie(ABBV)'s current trading volume is 4.12M, compared to an average daily volume of 7M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $249.59 and a 52-week low of $181.73.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $249.59 and a 52-week low of $181.73.
ABBV News
Goldman Sachs analyst Asad Haider maintained a Hold rating on AbbVie on June 22 and set a price target of $244.00. TipRanks' Prime Week Sale - 70% Off Unlock po...
AbbVie (NYSE:ABBV) received European Commission approval for Skyrizi to treat children and adolescents with moderate to severe plaque psoriasis. The company al...
Key Points AbbVie is aggressively expanding its pipeline to offset the impact of biosimilar competition for its top-selling drugs. Pfizer is utilizing substan...
Analyst ratings
73%
of 33 ratingsMore ABBV News
Pharmaceutical giant AbbVie (ABBV +2.44%) made a bold move this past Monday when it announced its planned $10.9 billion acquisition of Apogee Therapeutics (APGE...
Why I Can’t Stop Buying This Unstoppable Dividend Juggernaut By Alex Sirois Published Jun 24, 4:33PM EDT Quick Read ABBV's Skyrizi and Rinvoq drove the immuno...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more conf...
Allergan Aesthetics, an AbbVie (ABBV) company, announced Health Canada has approved Boey for the temporary improvement in the appearance of moderate to severe l...
Key Points The deal gives the company a strong asset in zumilokibart, Apogee's very promising investigational drug. Apogee stockholders are to be paid $135.11...
Apogee Therapeutics (NASDAQ:APGE), a clinical-stage biologics company for inflammatory and immunology disorders, closed at $132.55, up 46.66%. AbbVie’s proposed...
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Monday. Shares of Apogee Therapeutics Inc (NASDAQ:APGE) rose sharply on Monda...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.